@ohsuknight.bsky.social
A leader in cancer research, the OHSU Knight Cancer Institute provides individually-tailored, compassionate care for patients, from diagnosis through survivorship.
@ohsuknight.bsky.social“When Doc walks in, I don’t have to explain anything. It’s a different way of showing how much you care for another being, and I really appreciate that OHSU recognizes that. He’s just a good boy. And he brings people joy.” - Patient, Angela Allen on therapy dog, Doc:
@ohsuknight.bsky.socialThe 'Doc' is in 🐕 Through a partnership with Assistance Dogs Northwest, Doc comforts patients at the OHSU Knight Cancer Institute. Doc joins Casey and Darby to make a special trio of OHSU paw-fessionals dedicated to supporting patients, families, and caregivers:
@ohsuknight.bsky.social“When we’re designing systems for healthcare, we forget that we’re designing the systems for the patient. The system designs the system for itself, and then we try to adjust it to the patient.”
- Dr. Eneida Nemecek at the TIME100 Health Leadership Forum: https://bit.ly/4xWMbFE
@ohsuknight.bsky.socialCongratulations to @meganburgerphd.bsky.social on receiving a MERIT Award from the National Cancer Institute for her project, “Antigen immunodominance in regulation of anti-tumor CD8 T cell immunity and immunotherapy response.”
Learn more ➡️ https://bit.ly/3VjURZ1
@ohsuknight.bsky.social"I see PSI as a way to pay forward the work of the mentors I had in high school and college who were crucial to setting me on the path of becoming a scientist."
- Sam King, an M.D., Ph.D. student in the Donald Conrad lab, who volunteers in the PSI program: https://bit.ly/4hCn6tu
@ohsuknight.bsky.social“This is a really exciting study that is responsive to the needs of our clinical and patient partners."
- Dr. Melinda Davis on receiving funding to help address barriers that prevent patients from getting cancer screenings: https://bit.ly/4ADQqbu
@ohsuknight.bsky.socialCongratulations to Dr. Melinda Davis on receiving a multi-phase award from the National Cancer Institute to help address barriers that prevent patients across Oregon from getting cancer screenings.
Learn more: https://bit.ly/4ADQqbu
@ohsuknight.bsky.socialHigh school students spent the summer stepping into biomedical research, working alongside scientists, attending lectures, and gaining hands-on laboratory experience through the OHSU Neuro-Oncology Blood-Brain Barrier Program.
Learn more ➡️ https://bit.ly/4hCn6tu
@ohsuknight.bsky.social“We screen for just five cancers, yet the ones we can't screen for cause up to 70% of cancer deaths in this country; that’s the gap this blood test helps close.” - Dr. Nima Nabavizadeh
@ohsuknight.bsky.social“One of the surprising findings is that antioxidants aren't always beneficial in the context of cancer.”
- Dr. Robert Eil on #OHSUResearch that found tumors can evade the immune system by releasing the antioxidant protein PRDX1 (via @fox12oregon.bsky.social):
@ohsuknight.bsky.social“One of the surprising findings is that antioxidants aren't always beneficial in the context of cancer.”
- Dr. Robert Eil on #OHSUResearch that found tumors can evade the immune system by releasing the antioxidant protein PRDX1 (via @fox12oregon.bsky.social):
@ohsuknight.bsky.socialToday, we announced our inaugural board of directors, uniting leaders from healthcare, Fortune 500 companies, public policy, philanthropy, research, and more to guide the organization’s next phase of growth. Learn more: https://bit.ly/4hqishU
@ohsuknight.bsky.socialNew findings from the PATHFINDER 2 study show that adding a multi-cancer early detection blood test to recommended #cancer screening increased the number of cancers detected by 6.5 times. https://news.ohsu.edu/2026/09/22/pathfinder-2-findings-advance-multi-cancer-early-detection-blood-testing
@ohsuknight.bsky.social“I think we’ve just scratched the surface of what we can do with these ultrasound-responsive biomaterials.”
- Dr. Carolyn Schutt Ibsen, whose research focuses on developing ultrasound-responsive liposomes that encapsulate therapeutic materials like DNA.
Learn more: https://bit.ly/4yDF6up
@ohsuknight.bsky.social“Before I retire, I'd really like to be able to cure it [CML]. You know, take it from well-controlled, taking a pill a day to completely eradicate it.”
- Dr. Brian Druker on #WorldCMLDay:
@ohsuknight.bsky.social"It's been the honor of my life to fight for my patients and to see Gleevec give hundreds of thousands of people their lives back.”
- Dr. Brian Druker reflecting on the 25th anniversary of Gleevec's FDA approval #WorldCMLDay:
@ohsuknight.bsky.socialIn 1998, Mel Mann was told he had #CML and that he had three years to live.
Fast forward to 2026 ⏩ Mel's still healthy and training for his next marathon. 🏃
On this #WorldCMLDay, listen to Mel's story (via @npr.org):
@ohsuknight.bsky.social“I think we’ve just scratched the surface of what we can do with these ultrasound-responsive biomaterials.”
- Dr. Carolyn Schutt Ibsen, whose research focuses on developing ultrasound-responsive liposomes that encapsulate therapeutic materials like DNA.
Learn more: https://bit.ly/4yDF6up
@ohsuknight.bsky.social“I think we’ve just scratched the surface of what we can do with these ultrasound-responsive biomaterials.”
- Dr. Carolyn Schutt Ibsen, whose research focuses on developing ultrasound-responsive liposomes that encapsulate therapeutic materials like DNA.
Learn more: https://bit.ly/4yDF6up
@ohsuknight.bsky.social“What's exciting is that we've identified a target nobody was really looking for before. Discovering new targets is how future treatments begin.” - Dr. Robert Eil on identifying potential therapeutic targets in tumors that evade the immune system:
